北米のラジオイムノアッセイ市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2030 |
 市場規模（基準年） |
|
 Market Size (Forecast Year) |
USD 407.20 |
 CAGR |
% |
| 主要市場プレーヤー |
>北米の放射免疫測定市場、製品タイプ別（放射免疫測定試薬およびキット、放射免疫測定分析装置）、用途別（科学研究および臨床診断）、エンドユーザー別（病院、臨床診断研究所、学術研究機関、製薬およびバイオ製薬業界、契約研究機関、その他）、流通チャネル別（直接入札、オンライン販売、第三者流通、その他）の業界動向と2030年までの予測。
北米のラジオイムノアッセイ市場の分析と洞察
さまざまな病気の医療蔓延の増加により、治療目的の医療分野での研究の増加、検査に使用される放射免疫測定キットを使用した内分泌学や感染症などのさまざまな検査、および医療費の増加もビジネスの成長を促進するでしょう。さまざまな病気の事前検査のための臨床研究と研究室により、市場は拡大します。
北米の放射免疫測定市場は、2023年から2030年の予測期間に成長すると予想されています。Data Bridge Market Researchは、市場は2023年から2030年の予測期間に4.4%のCAGRで成長し、2030年までに4億720万米ドルに達すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2020～2016年にカスタマイズ可能) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
製品タイプ別（放射性免疫測定試薬およびキット、放射性免疫測定分析装置）、用途別（科学研究および臨床診断）、エンドユーザー別（病院、臨床診断研究所、学術研究機関、製薬およびバイオ製薬業界、契約研究機関、その他）、流通チャネル別（直接入札、オンライン販売、第三者流通、その他）。 |
|
対象国 |
米国、カナダ、メキシコ |
|
対象となる市場プレーヤー |
市場で取引している主要企業としては、PerkinElmer Inc.、KAMIYA BIOMEDICAL COMPANY、Beckman Coulter, Inc.、Abcam plc、MyBioSource.com、MP BIOMEDICALS、Tecan Trading AG などがあります。 |
市場の定義
ラジオイムノアッセイは、放射性標識された薬剤 (通常は 125i) を使用する異種アッセイであり、ラジオイムノアッセイの基盤となる競合結合アッセイ理論です。この方法では、抗原と抗体が互いに結合し、ラジオイムノアッセイを使用して結合した抗原の量を決定します。抗体の助けを借りて、この方法は超高感度であるため、ごく微量のホルモンや薬剤レベルでも検出できます。
Due to the rise in healthcare prevalence of various diseases, increased research in the healthcare sector for therapeutic purposes, and various testing like endocrinology and infectious diseases by using radioimmunoassay kits used for testing and increasing healthcare spending would also propel business growth. The clinical research and laboratories for pre-testing various diseases allow the market to expand.
With this increasing number of such severe diseases like cancer and infections and healthcare awareness, the growth of laboratory testing has led to increased demand for various kits for testing. This aspect also contributes to the rising demand for reagents and kits.
The North America radioimmunoassay market is growing in the forecast year due to the rise in market players and the availability of advanced kits and analyzers. Along with this, manufacturers are engaged in R&D activity for launching products in the market. The increasing research and developments and pre-testing further boost the market growth. However, another immunoassay testing technique dominates radioimmunoassay, which might hamper the growth of the North America radioimmunoassay market in the forecast period.
North America Radioimmunoassay Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
INCREASE IN THE DEMAND FOR ERROR-FREE AND ACCURATE RESULTS OF HIGH THROUGHPUT AND AUTOMATED PROCEDURES
Radioimmunoassay is a heterogeneous assay that employs a radiolabeled drug (typically 125i), the competitive binding assay theory that underpins radioimmunoassay. In this method, antigen and antibody bind to one another, and radioimmunoassay is used to determine how much antigen is bound.
Therefore, due to the increasing number of such severe diseases and viruses, the growth of biological models has been largely seen in recent years. This has increased the demand for error-free and accurate results from biological samples.
RISE IN THE PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES
Infectious diseases are illnesses caused by harmful agents (pathogens) entering the body. The most common causes are viruses, bacteria, fungi, and parasites. Infectious diseases usually spread from person to person through contaminated food or water and bug bites. Some infectious diseases are minor, and some are very serious.
Thus, rising number of cases of infectious, the growth of biological models has been largely seen in recent years. This has led to increased demand for various radioimmunoassay techniques for detecting and studying these aspects, which is expected to drive the market's growth in the coming years.
Restraints
HIGH COST OF INSTALLATION AND MAINTENANCE OF RADIOIMMUNOASSAY KITS
The cost of radioimmunoassay kits is a major setback for the market as it is expected to decrease the demand due to high costs.
Therefore, increasing research and development in the life science domain leads to more advancement in radioimmunoassay techniques. That advancement is continuously increasing the price of the radioimmunoassay and its units, which may hamper the growth of the North America radioimmunoassay market.
SHORT SHELF-LIFE OF RADIOLABELED COMPOUNDS
Chemical compounds decompose over time during storage. The rate at which this takes place is specific to the compound. However, compounds labeled with radioisotopes typically decompose faster than their unlabeled counterparts due to radiolytic decomposition.
Hence, the utmost care needed to be taken for the storage usage of radiolabelled isotopes in radioimmunoassay techniques for its prevention from decomposition act as a restraining factor for the North America radioimmunoassay market.
Opportunities/Challenges
LACK OF SKILLED PROFESSIONALS
The radioimmunoassay technique is very advanced and sensitive enough to find small molecules in the blood. It is therefore used for research purposes and diagnosing diseases such as cancer. Organizations and research labs also implement this technique for specific research purposes that use animal or human serum. However, the lack of qualified personnel who cannot use these instruments could curb the growth of the radioimmunoassay market over a forecast period.
Moreover, rapid technological advancement in this field also led to the lack of skilled professionals. Lack of skilled professionals poses a major challenge while handling device devices worldwide.
Recent Developments
- In April 2022, Merck, a leading science and technology company, announced several organizational changes and a new operating model to support the life science business sector's long-term growth strategy and better serve its customers' evolving needs. This has helped the company to expand its life sciences business segment.
- In June 2022, EUROIMMUN, a PerkinElmer, Inc. company, announced the launch of two CE-marked assays – the Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG). Both test systems enable the detection of IgG antibodies formed against SARS-CoV-2 and are available to laboratories in countries that accept the CE mark. This has helped the company to expand its business in the market.
North America Radioimmunoassay Market Scope
North America radioimmunoassay market is segmented into product type, application, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
By Product Type
- Radio Immunoassay Reagents and Kits
- Radio Immunoassay Analyzer
On the basis of product type, the North America radioimmunoassay market is segmented into radio immunoassay reagents and kits and radio immunoassay analyzer.
By Application
- Clinical Diagnosis
- Scientific Research
On the basis of application, the North America radioimmunoassay market is segmented into clinical diagnosis and scientific research.
By End user
- Hospitals
- Clinical Diagnostic Laboratories
- Academic And Research Institutes
- Pharmaceutical And Biopharmaceutical Industry
- Contract Research Organizations
- Others
On the basis of end user, the North America radioimmunoassay market is segmented into hospitals, clinical diagnostic laboratories, academic and research institutes, pharmaceutical and biopharmaceutical industry, contract research organisations, and others.
By Distribution Channel
- Direct Tender
- Online Sales
- Third Party Distributions
- Others
On the basis of distribution channel, the North America radioimmunoassay market is segmented into direct tender, online sales, third party distributions and others.
North America Radioimmunoassay Market Regional Analysis/Insights
The North America radioimmunoassay market is analyzed, and market size insights and trends are provided by product type, application, end user, and distribution channel, as referenced above.
The countries covered in the report are U.S., Canada, and Mexico.
U.S. dominates the North America radioimmunoassay market regarding market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the rising technological advancements in microscopy in that region, and growing R&D investments and the launch of new products are boosting the market
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Radioimmunoassay Market Share Analysis
The competitive radioimmunoassay landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies focusing on the radioimmunoassay market.
Some of the major players operating in the North America radioimmunoassay Market are PerkinElmer Inc., KAMIYA BIOMEDICAL COMPANY, Beckman Coulter, Inc., Abcam plc., MyBioSource.com., MP BIOMEDICALS, and Tecan Trading AG, among others.
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA RADIOIMMUNOASSAY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTYER’S FIVE FORCES
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS
5 INDUSTRY INSIGHTS:
6 REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY
6.1 U.S REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY
6.2 EUROPE REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY
6.3 INDIA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY
6.4 CHINA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN THE DEMAND FOR ERROR-FREE AND ACCURATE RESULTS OF HIGH THROUGHPUT AND AUTOMATED PROCEDURES
7.1.2 RISE IN THE PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES
7.1.3 RISE IN THE TECHNOLOGICAL ADVANCEMENTS
7.2 RESTRAINTS
7.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF RADIOIMMUNOASSAY KITS
7.2.2 SHORT SHELF-LIFE OF RADIOLABELED COMPOUNDS
7.2.3 ADVERSE EFFECTS OF HAZARDOUS RADIOACTIVE ELEMENTS
7.3 OPPORTUNITIES
7.3.1 INCREASING SIGNIFICANCE OF RESEARCH AND DEVELOPMENT IN MEDICAL SCIENCE
7.3.2 RISE IN GOVERNMENT FUNDING AND OVERALL HEALTHCARE EXPENDITURE
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS
7.4.2 NEW INNOVATIONS IN VARIOUS OTHER IMMUNOASSAY PROCEDURES
8 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 RADIOIMMUNOASSAY REAGENTS AND KITS
8.2.1 KITS
8.2.2 BUFFER
8.2.2.1 SOLUTION
8.2.2.2 POWDER
8.2.3 STANDARD CONCENTRATES
8.2.4 PRECIPITATING REAGENTS
8.2.5 RADIOISOTOPES
8.2.5.1 BETA EMITTERS
8.2.5.1.1 TRITIUM
8.2.5.1.2 CARBON-14
8.2.5.2 GAMMA EMITTERS
8.2.5.2.1 IODINE-125
8.2.5.2.2 CHROMIUM-51
8.2.5.2.3 COBALT-57
8.2.6 ANTIBODY/ANTISERUM
8.2.6.1 POLYCLONAL
8.2.6.2 MONOCLONAL
8.2.7 OTHERS
8.3 RADIOIMMUNOASSAY ANALYZER
9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION
9.1 OVERVIEW
9.2 SCIENTIFIC RESEARCH
9.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.2.2 RADIOIMMUNOASSAY ANALYZER
9.3 CLINICAL DIAGNOSIS
9.3.1 INFECTIOUS DISEASE TESTING
9.3.1.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.1.2 RADIOIMMUNOASSAY ANALYZER
9.3.2 ALLERGY TESTING
9.3.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.2.2 RADIOIMMUNOASSAY ANALYZER
9.3.3 ONCOLOGY TESTING
9.3.3.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.3.2 RADIOIMMUNOASSAY ANALYZER
9.3.4 ENDOCRINE TESTING
9.3.4.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.4.2 RADIOIMMUNOASSAY ANALYZER
9.3.5 TOXICOLOGY TESTING
9.3.5.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.5.2 RADIOIMMUNOASSAY ANALYZER
9.3.6 AUTOIMMUNE DISEASE TESTING
9.3.6.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.6.2 RADIOIMMUNOASSAY ANALYZER
9.3.7 OTHER DISEASE TESTING
10 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICAL DIAGNOSTIC LABORATORIES
10.4 ACADEMIC AND RESEARCH INSTITUTES
10.5 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY
10.6 CONTRACT RESEARCH ORGANISATIONS
10.7 OTHERS
11 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 ONLINE SALES
11.4 THIRD PARTY DISTRIBUTIONS
11.5 OTHERS
12 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 PERKINELMER INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 MERCK KGAA
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 BECKMAN COULTER, INC.
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 ABCAM PLC
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 TECAN TRADING AG
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 BERTHOLD TECHNOLOGIES GMBH & CO.KG
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 DEMEDITEC DIAGNOSTICS GMBH
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 DIASOURCE
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 HIDEX OY
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 IMMUNO-BIOLOGICAL LABORATORIES CO,LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 INSTITUTE OF ISOTOPES
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 KAMIYA BIOMEDICAL COMPANY
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 MP BIOMEDICALS
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 MYBIOSOURCE.COM.
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表のリスト
TABLE 1 LIST OF IN-VITRO DIAGNOSTIC MEDICAL DEVICES (IVD ANALYZERS) UNDER PROVISIONS OF SUB-RULE (2) RULE 4 OF THE MEDICAL DEVICES RULES, 2017
TABLE 2 COST OF RIA KITS IS MENTIONED BELOW
TABLE 3 DECOMPOSITION RATES OF A FEW RADIOLABELED ISOTOPES ARE MENTIONED IN THE BELOW TABLE
TABLE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA RADIOIMMUNOASSAY ANALYZER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA HOSPITALS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA CLINICAL DIAGNOSTIC LABORATORIES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA CONTRACT RESEARCH ORGANISATIONS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA DIRECT TENDER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA ONLINE SALES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA THIRD PARTY DISTRIBUTION IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 40 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 41 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 43 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 44 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 47 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 48 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 50 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 51 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 52 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 53 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 54 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 55 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 56 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 67 U.S. RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 70 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 71 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 73 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 74 U.S. RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 77 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 78 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 80 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 81 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 82 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 83 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 84 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 85 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 86 U.S. RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 U.S. SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 U.S. CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 89 U.S. INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 U.S. ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 U.S. ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 U.S. ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 U.S. TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 94 U.S. AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.S. RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 U.S. RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 CANADA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 100 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 101 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 103 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 104 CANADA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 105 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 107 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 108 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 110 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 111 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 112 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 113 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 114 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 115 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 116 CANADA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 117 CANADA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 CANADA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 119 CANADA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 CANADA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 CANADA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 CANADA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 CANADA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 124 CANADA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 CANADA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 CANADA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 MEXICO RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 129 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 130 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 131 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 132 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 133 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 134 MEXICO RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 137 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 138 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 140 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 141 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 142 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 143 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 144 MEXICO RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 145 MEXICO RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 146 MEXICO RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 147 MEXICO SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 148 MEXICO CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 149 MEXICO INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 MEXICO ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 MEXICO ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 152 MEXICO ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 MEXICO TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 154 MEXICO AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 MEXICO RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 156 MEXICO RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA RADIOIMMUNOASSAY: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA RADIOIMMUNOASSAY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA RADIOIMMUNOASSAY MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA RADIOIMMUNOASSAY MARKET IN THE FORECAST PERIOD
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA RADIOIMMUNOASSAY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA RADIOIMMUNOASSAY MARKET
FIGURE 14 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA RADIOIMMUNOASSAY MARKET: PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, 2022
FIGURE 19 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, 2022
FIGURE 23 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA RADIOIMMUNOASSAY MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 27 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SNAPSHOT (2022)
FIGURE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2022)
FIGURE 32 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 NORTH AMERICA RADIOIMMUNOASSAY MARKET: PRODUCT TYPE (2023-2030)
FIGURE 35 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
